Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

The Top 5 Analyst Questions From Haemonetics’s Q2 Earnings Call

HAE Cover Image

Haemonetics’ second quarter results were met with a significant negative market reaction, reflecting concerns about declining revenue despite exceeding Wall Street expectations. Management attributed the 4.4% year-over-year sales decline mainly to planned portfolio transitions, including divestitures and contract changes, while emphasizing strong growth in its base business. CEO Christopher Simon highlighted that “85% of total revenue is now driven by three core products—NexSys, TEG, and VASCADE—anchored in the U.S.,” underscoring a more focused and resilient portfolio. However, operational challenges, particularly within Interventional Technologies, and increased competition in vascular closure were called out as key issues impacting performance.

Is now the time to buy HAE? Find out in our full research report (it’s free).

Haemonetics (HAE) Q2 CY2025 Highlights:

  • Revenue: $321.4 million vs analyst estimates of $301.6 million (4.4% year-on-year decline, 6.6% beat)
  • Adjusted EPS: $1.10 vs analyst estimates of $1.02 (8.3% beat)
  • Adjusted EBITDA: $102.1 million vs analyst estimates of $93.68 million (31.8% margin, 9% beat)
  • Management reiterated its full-year Adjusted EPS guidance of $4.85 at the midpoint
  • Operating Margin: 16.8%, up from 11.8% in the same quarter last year
  • Organic Revenue was flat year on year vs analyst estimates of 5.1% declines (561.5 basis point beat)
  • Market Capitalization: $2.60 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Haemonetics’s Q2 Earnings Call

  • Rohin Patel (JPMorgan): Asked about the sustainability of plasma share gains and details on the software agreement’s impact. CEO Christopher Simon explained roughly half of plasma organic growth was from the software deal, with ongoing share gains expected to drive growth through the year.

  • Anthony Petrone (Mizuho): Inquired about timing for full deployment of plasma share gains and strategic focus. Simon noted share conversions are ahead of schedule and expected to continue into next year, with R&D and patent defense remaining priorities.

  • David Rescott (Baird): Pressed on confidence behind the anticipated recovery in Interventional Technologies. Simon acknowledged current outperformance in Blood Management Technologies is offsetting underperformance, with recovery in Interventional Technologies expected in the second half through targeted investments.

  • Andrew Cooper (Raymond James): Sought specifics on actions being taken to address vascular closure execution. Simon detailed sales and marketing leadership hires, organizational restructuring, and new account management strategies to strengthen competitiveness, while cautioning improvement will be gradual.

  • Michael Petusky (Barrington Research): Queried the cadence of margin improvements and competitive pressures in Interventional Technologies. CFO James D’Arecca indicated margin gains will be more pronounced in the second half, and Simon described the leadership overhaul as part of a broader turnaround effort.

Catalysts in Upcoming Quarters

In the coming quarters, our team will monitor (1) the pace of plasma center upgrades and further customer conversions to NexSys, (2) sustained adoption and geographic expansion of TEG 6s and heparinase neutralization cartridges, and (3) evidence of operational turnaround in Interventional Technologies, particularly improvement in vascular closure execution. Additionally, the impact of ongoing portfolio restructuring and cost management on profitability will be key signposts for progress.

Haemonetics currently trades at $53.99, down from $75.74 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.